# A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

> **NCT06854640** · PHASE1 · RECRUITING · sponsor: **Bayer** · enrollment: 36 (estimated)

## Conditions studied

- Sepsis
- Coagulopathy

## Interventions

- **DRUG:** BAY3389934

## Key facts

- **NCT ID:** NCT06854640
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2026-12-25
- **Final completion:** 2027-02-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06854640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06854640, "A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06854640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*